amikacin
Antiinfectives for systemic use (J01)Antiinfectives for systemic use (J01) compound in Moleculin Biotech's portfolio.
biotech · Acute Myeloid Leukemia · Sarcoma,Soft Tissue · MBRX
Moleculin Biotech
Moleculin Biotech drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Houston, USA HQ
2006 Founded
22 Employees
Public company Type
MBRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Houston, USA
- Founded
- 2006
- Employees
- 22
- Programs
- 9
- Drugs
- 10
- Patents
- 1
Moleculin Biotech pipeline
Portfolio lens on 10 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Moleculin Biotech drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Moleculin Biotech in public FDA and regional records.
-
Development asset linked to Moleculin Biotech in public FDA and regional records.
-
cytarabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to Moleculin Biotech in public FDA and regional records.
-
Development asset linked to Moleculin Biotech in public FDA and regional records.
-
Development asset linked to Moleculin Biotech in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Moleculin Biotech in public FDA and regional records.